{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:38:17Z","timestamp":1793446697088,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clgc.2024.102138","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T05:25:00Z","timestamp":1718169900000},"page":"102138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-7888","authenticated-orcid":false,"given":"Fabio","family":"Turco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Buttigliero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Donatello","family":"Delcuratolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula Maria","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Farinea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario Francesco","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Saporita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Crespi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Poletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Palesandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Vittorio","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102138_bib0001","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMe0901737","article-title":"Androgen deprivation in prostate cancer\u2013step by step","volume":"360","author":"Albertsen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0002","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0022-5347(02)80307-X","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"167","author":"Huggins","year":"1972","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0003","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0004","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0005","doi-asserted-by":"crossref","first-page":"64447","DOI":"10.18632\/oncotarget.10901","article-title":"Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer","volume":"7","author":"Wadosky","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2024.102138_bib0006","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0009","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. part I: screening, diagnosis, and local treatment with curative intent","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0011","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"Prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2024.102138_bib0012","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.eururo.2015.11.023","article-title":"Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review","volume":"69","author":"van den Bergh","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0013","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1007\/s00345-021-03611-x","article-title":"Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review","volume":"39","author":"Devos","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2024.102138_bib0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0090-4295(01)01245-6","article-title":"Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer","volume":"58","author":"Meyer","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2024.102138_bib0016","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/jcp.55.7.508","article-title":"Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer","volume":"55","author":"Selli","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.clgc.2024.102138_bib0017","first-page":"5030","article-title":"Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process","volume":"59","author":"Craft","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2024.102138_bib0018","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11934-016-0592-4","article-title":"Neoadjuvant treatment of high-risk, clinically localized prostate cancer prior to radical prostatectomy","volume":"17","author":"Pietzak","year":"2016","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.clgc.2024.102138_bib0019","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.urolonc.2019.07.009","article-title":"Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: a retrospective comparative study","volume":"37","author":"Pan","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0020","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and leukemia group B 90203 (alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0021","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1158\/0008-5472.CAN-06-3332","article-title":"Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer","volume":"67","author":"Mostaghel","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2024.102138_bib0022","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0023","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1158\/1078-0432.CCR-23-0731","article-title":"Neoadjuvant cabazitaxel plus abiraterone\/leuprolide acetate in patients with high-risk prostate cancer: ACDC-RP phase II trial","volume":"29","author":"Fleshner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2024.102138_bib0024","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.euo.2020.08.005","article-title":"Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review","volume":"3","author":"Marra","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0025","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0026","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.eururo.2008.05.023","article-title":"Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy","volume":"54","author":"Schumacher","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006019","article-title":"Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer","volume":"2006","author":"Kumar","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clgc.2024.102138_bib0028","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1200\/JCO.2017.76.4126","article-title":"Phase III intergroup trial of adjuvant androgen deprivation with or without mitoxantrone plus prednisone in patients with high-risk prostate cancer after radical prostatectomy: SWOG S9921","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0029","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0360-3016(88)90383-5","article-title":"Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study","volume":"14","author":"Zagars","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2024.102138_bib0030","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2024.102138_bib0031","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A hormone-DNA repair circuit governs the response to genotoxic insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2024.102138_bib0032","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0033","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.24392","article-title":"Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials","volume":"115","author":"Bria","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2024.102138_bib0034","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0035","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0036","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0037","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0038","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2019.08.010","article-title":"Docetaxel versus surveillance after radical radiotherapy for intermediate- or high-risk prostate cancer-results from the prospective, randomised, open-label phase III SPCG-13 trial","volume":"76","author":"Kellokumpu-Lehtinen","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0039","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102138_bib0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0041","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0042","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102138_bib0043","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clgc.2024.102138_bib0044","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2023.04.010","article-title":"Genomic classifier performance in intermediate-risk prostate cancer: results from NRG oncology\/RTOG 0126 randomized phase 3 trial","volume":"117","author":"Spratt","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2024.102138_bib0045","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2024.102138_bib0046","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions","volume":"11","author":"Paller","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0047","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.juro.2009.08.027","article-title":"Radiation therapy after radical prostatectomy: impact on metastasis and survival","volume":"182","author":"Boorjian","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0048","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0049","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0051","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0052","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External validation of the european association of urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a european cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0053","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.euo.2018.12.011","article-title":"Nonsurgical salvage local therapies for radiorecurrent prostate cancer: a systematic review and meta-analysis","volume":"3","author":"Ingrosso","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"10442","key":"10.1016\/j.clgc.2024.102138_bib0054","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102138_bib0055","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0056","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0057","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0058","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0059","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0060","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0061","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0062","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0063","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0064","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/iju.12005","article-title":"Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective","volume":"20","author":"Ahmed","year":"2013","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0066","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0067","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2015.09.013","article-title":"Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis","volume":"69","author":"Tucci","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0068","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0069","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102138_bib0070","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0071","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","article-title":"Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer","volume":"34","author":"Rusthoven","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0072","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102138_bib0073","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0074","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMc2205310","article-title":"Darolutamide in metastatic prostate cancer","volume":"386","author":"Turco","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0075","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0076","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1200\/JCO.2012.46.5492","article-title":"Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials","volume":"31","author":"Niraula","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1391825","article-title":"EORTC 2238 \"de-escalate\": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors","volume":"14","author":"Grisay","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0078","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0079","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0080","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102138_bib0081","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0082","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0083","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clgc.2024.102138_bib0084","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bju.14876","article-title":"TheraP: a randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (clinical trial protocol ANZUP 1603)","volume":"124","author":"Hofman","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2024.102138_bib0085","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102138_bib0086","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0087","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1016\/j.clgc.2016.12.015","article-title":"Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer","volume":"15","author":"Miyake","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2024.102138_bib0088","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2014.06.045","article-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","volume":"67","author":"Azad","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0089","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clgc.2017.09.008","article-title":"Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"16","author":"Matsubara","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2024.102138_bib0090","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.eururo.2017.09.022","article-title":"Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-na\u00efve prostate cancer in the GETUG-AFU 15 phase 3 trial","volume":"73","author":"Lavaud","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102138_bib0091","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0092","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102138_bib0093","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clgc.2024.102138_bib0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ijms25010078","article-title":"Synthetic lethality by co-inhibition of androgen receptor and polyadenosine diphosphate-ribose in metastatic prostate cancer","volume":"25","author":"Calabrese","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clgc.2024.102138_bib0096","article-title":"Targeted inhibition of CYP11A1 in castration-resistant prostate cancer","volume":"3","author":"Fizazi","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clgc.2024.102138_bib0097","first-page":"9","article-title":"How to improve the quality of life of patients with prostate cancer treated with hormone therapy?","volume":"15","author":"Turco","year":"2023","journal-title":"Res Rep Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:57:11Z","timestamp":1738565831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1558767324001095"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102138","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102138"}}